Int J Gynecol Cancer. 2018 May;28(4):657-665. doi: 10.1097/IGC.0000000000001167.
We conducted a multicenter clinicopathological study to characterize patients with high-grade serous carcinoma presenting as primary peritoneal carcinoma (clinical PPC).
At 9 sites in Japan, patients with clinical PPC diagnosed according to Gynecologic Oncology Group criteria were enrolled retrospectively. The Gynecologic Oncology Group criteria allow for minor ovarian involvement by high-grade serous carcinoma. There was no systematic detailed histopathological review of the fallopian tubes to determine whether they were involved by serous carcinoma.
There were 139 patients and 64% were aged 60 years or older. Median pretreatment serum CA-125 was 1653.5 IU/mL. Pretreatment performance status was poor in more than 50%, endometrial cytology was positive in 40.3%, and the preoperative clinical diagnosis was correct in 72.7%. Primary debulking surgery was performed in 36% of patients, whereas 64% underwent neoadjuvant chemotherapy (NAC) with interval debulking surgery (IDS). The main tumor sites were the upper abdomen (greater omentum), extrapelvic peritoneum, mesentery, and diaphragm. Lymph node metastasis was found in 46.8% of patients undergoing systematic retroperitoneal node dissection. The optimal surgery rate was 32.0% with primary debulking surgery versus 53.9% with NAC and IDS (P = 0.0139). The response rate was 82.0% with NAC and 80.6% with postoperative chemotherapy. Median progression-free survival was 19.0 months and median overall survival was 41.0 months. Multivariate analysis showed that prognostic factors for progression-free survival were NAC and residual tumor diameter after debulking surgery, whereas the only prognostic factor for overall survival was the residual tumor diameter.
This study identified various characteristics of clinical PPC. Neoadjuvant chemotherapy with IDS is a reasonable treatment strategy, and complete debulking surgery is optimum.
我们进行了一项多中心临床病理研究,以描述表现为原发性腹膜癌(临床 PPC)的高级别浆液性癌患者。
在日本的 9 个地点,回顾性招募了根据妇科肿瘤学组(Gynecologic Oncology Group,GOG)标准诊断为临床 PPC 的患者。GOG 标准允许高级别浆液性癌对卵巢有轻微累及。对于输卵管,没有系统的详细组织病理学检查来确定它们是否被浆液性癌累及。
共有 139 名患者,其中 64%的患者年龄在 60 岁或以上。中位预处理血清 CA-125 为 1653.5 IU/mL。预处理表现状态不佳的患者超过 50%,子宫内膜细胞学阳性率为 40.3%,术前临床诊断准确率为 72.7%。36%的患者接受了初次减瘤手术,而 64%的患者接受了新辅助化疗(NAC)联合间隔减瘤手术(IDS)。主要肿瘤部位在上腹部(大网膜)、盆外腹膜、肠系膜和膈肌。系统腹膜后淋巴结清扫术发现 46.8%的患者有淋巴结转移。原发性减瘤手术的最佳手术率为 32.0%,而 NAC 和 IDS 的最佳手术率为 53.9%(P=0.0139)。NAC 的缓解率为 82.0%,术后化疗的缓解率为 80.6%。中位无进展生存期为 19.0 个月,中位总生存期为 41.0 个月。多因素分析显示,无进展生存期的预后因素是 NAC 和减瘤手术后的残余肿瘤直径,而总生存期的唯一预后因素是残余肿瘤直径。
本研究确定了临床 PPC 的各种特征。IDS 联合 NAC 是一种合理的治疗策略,完全减瘤手术是最佳选择。